Skip to main content

NCT00656097 - A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combinati

A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects


CSR Summary

Not Yet Available


Primary Citation

Trial has yet to be published


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Rafivirumab/Foravirumab
Product Name
Therapeutic Area
Viral Diseases
Enrollment
140
% Female
N/A
% White
N/A
Product Class
Immunizations
Sponsor Protocol Number
RAB-M-A003
Data Partner
Johnson & Johnson
Condition Studied
Rabies
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Collected Datasets
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.